Ann Surg Oncol. 2026 Mar 3. doi: 10.1245/s10434-026-19379-6. Online ahead of print.
ABSTRACT
PURPOSE: Our objective was to evaluate clinical outcomes and vascular graft patency following portal vein/superior mesenteric vein (PV/SMV) reconstruction using recanalized autologous ligamentum teres hepatis (LTH) grafts.
METHODS: This study enrolled 387 patients, stratified into three groups: (1) pancreaticoduodenectomy alone, (2) pancreaticoduodenectomy with vascular resection and reconstruction via end-to-end anastomoses or lateral venorrhaphy, and (3) pancreaticoduodenectomy with PV/SMV resection and reconstruction using autologous LTH grafts. This retrospective study compared operative time, intraoperative blood loss, postoperative complication rates, mortality, and length of postoperative hospital stay across these groups.
RESULTS: The study included 336 patients who underwent pancreaticoduodenectomy, 23 who underwent pancreaticoduodenectomy with vascular resection and reconstruction via end-to-end anastomosis or lateral venorrhaphy, and 28 who underwent pancreaticoduodenectomy with PV/SMV resection and reconstruction using autologous LTH grafts. The group using autologous LTH grafts exhibited an operative time of 484.86 ± 103.77 (285-685) min; intraoperative blood loss of 236.79 ± 141.95 (80-800) mL; a postoperative complication rate of 42.86%; 30-day mortality rate of 7.14%; and postoperative hospital stay of 20.82 ± 8.25 (9-49) days. Statistical analysis revealed a significantly longer operative time in the autologous LTH grafts group than in the other groups (p < 0.001), with no significant intergroup differences in blood loss, postoperative complication rates, mortality, or hospitalization. Partial thrombosis involving ≤50% of vessel diameter without obstruction was observed in four cases involving autologous LTH grafts. All reconstructed vessels maintained 100% patency throughout the follow-up period.
CONCLUSIONS: Using autologous LTH grafts for PV/SMV reconstruction during pancreaticoduodenectomy was safe and feasible, demonstrating favorable vascular graft patency rates and supporting its role as a viable alternative conduit for vascular restoration.
PMID:41774366 | DOI:10.1245/s10434-026-19379-6